Manfred is a serial biotech entrepreneur and has been in executive functions in the biotech industry for almost 25 years. Currently, he is CEO of Ariceum Therapeutics, a clinical-stage radiopharmaceuticals company focused on the diagnosis and precision treatment of neuroendocrine and other aggressive, hard-to-treat cancers. Whilst at CatalYm (2018-2021), he built the company from incubator to clinical stage raising over €55 million. Prior to this, Manfred was Chairman of apceth Biopharma, where he led the negotiations during the acquisition of apceth by Hitachi in 2019. Manfred has been a venture partner with LSP (now EQT Life Sciences) since 2009 and was appointed CEO of Kiadis Pharma N.V. in 2012 which he restructured and led to its IPO on Euronext in 2015 (subsequently acquired by Sanofi). Previously, he was Chief Scientific Officer of Cardion (asset sale to Roche) and CEO of Igeneon (merger with NASDAQ-listed Aphton) until 2005. Manfred currently also serves as Chairman of the Board of Thermosome and is on the Supervisory Board of 4SC AG.
Manfred holds a PhD in biochemistry for research at the MPI for Biophysical Chemistry, Göttingen, Germany and has served as an Assistant Professor teaching immunology and cell biology for five years at the University of Braunschweig.
„HeartBeat.bio is an exciting start-up based on top-notch, leading-edge science around cardiac organoids. I believe that organoid disease models and screening tools will become a key part of innovative cardiovascular research and drug development. I am excited to be part of this effort and to work with the team.“